AbbVie
ABBV
1,422 hedge funds and large institutions have $56.6B invested in AbbVie in 2014 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 493 increasing their positions, 656 reducing their positions, and 69 closing their positions.
98% more call options, than puts
Call options by funds: $312M | Put options by funds: $158M
4% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 69
0.09% less ownership
Funds ownership: 69.07% → 68.97% (-0.09%)
1% less funds holding
Funds holding: 1,435 → 1,422 (-13)
3% less capital invested
Capital invested by funds: $58B → $56.6B (-$1.46B)
14% less funds holding in top 10
Funds holding in top 10: 59 → 51 (-8)
25% less repeat investments, than reductions
Existing positions increased: 493 | Existing positions reduced: 656
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$177M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$118M |
| 3 |
D.E. Shaw & Co
New York
|
+$114M |
| 4 |
FAM
Fred Alger Management
New York
|
+$105M |
| 5 |
HCM
Highline Capital Management
New York
|
+$103M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$249M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$210M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$199M |
| 4 |
State Street
Boston,
Massachusetts
|
-$197M |
| 5 |
Lazard Asset Management
New York
|
-$151M |
ABBV Hedge Fund Activity: Q1 2014 in Review
1,422 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2014, worth a combined $56.6B — down 2.5% from $58B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new ABBV positions and 69 closed out — a net gain of 3 holders — while 493 added to existing stakes and 656 trimmed.
The largest buyer was Capital International Investors, adding an estimated $177M. The largest seller was T. Rowe Price Associates, cutting an estimated $249M.
- 1,422 institutional investors held AbbVie (ABBV) as of Q1 2014, down from 1,435 in Q4 2013.
- Funds reported $56.6B of AbbVie stock for Q1 2014, down 2.5% quarter-over-quarter.
- 72 funds opened new AbbVie positions in Q1 2014 and 69 closed out, a net change of +3 holders.
- The largest AbbVie buyer in Q1 2014 was Capital International Investors, an estimated $177M added.
- The largest AbbVie seller in Q1 2014 was T. Rowe Price Associates, an estimated $249M sold.
Based on aggregated 13F filings for Q1 2014.